Slide 1: Q1'23 Earnings Presentation
Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO Q1’23 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, Interim CFO April 25, 2023
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified b
Slide 3: CEO Summary: Q1'23 Highlights
CEO Summary: Q1’23 Highlights “A Strong Start to Realizing Our Profitable Growth Platform” Income Statement Components Q1' 2023 Q1' 2022 Revenue (GAAP) 30.0 28.8 Growth Rate 4% Unfavorable FX Impact 0.5 Net Reduction in Discontinued Products vs Q1’22 1.1 Gross Margin 18.3 16.2 % of Revenue 61% 56% A
Slide 4: 2023 Q1 Revenue by Product Family
2023 Q1 Revenue by Product Family (in $M) Q1 Q1 Comments 2023 2022 Vs. Q1’22 Cellular & 14.2* 14.2 flat Cellular and Molecular Product Revenue were down (2%) as reported, flat when Molecular adjusted for currency and includes impact from discontinued products o Solid growth in APAC offset by slownes
Slide 5: New Product Launches
New Product Launches Research & Discovery, Bridge to Bio-Production Pre-Clinical Toxicology & Safety Pharmacology MOLECULES CELLS ORGANOIDS PRECLINICAL CLINICAL /ORGANS High-Capacity SmartUssing™ Epithelial System STG5 Stimulation Generator Behavior Monitoring System Behavior Electrophysiology Elect
Slide 6: Financial Section
Financial Section 6
Slide 7: Q1'23 Performance versus Q1'22
Q1’23 Performance versus Q1’22 Revenue ($M) Revenue $30M, up 4% (-$0.5M Currency) Gross Margin (GAAP) 61.2% vs. 56.2% Adj. Operating Income* $4.4M vs. $2.4M $30.0 $28.8 Adj. EBITDA* $4.8M vs. $2.7M Q1'23 Q1'22 Cash Flow from Operations +$1.8M (3rd consecutive +Q) Adj. EBITDA Margin * Net Debt ** $41
Slide 8: 2023 Outlook
2023 Outlook 8
Slide 9: 2023 Outlook: Looking Forward
2023 Outlook: Looking Forward New Products and Services Expand Pharma, CROs and Research Growth For FY2023, we now expect: ▪ Reported revenue growth in the mid-single digits, includes approx. 4 percentage points of discontinued products compared to 2022 ▪ Gross Margins to remain strong in the 60% ra
Slide 10: Appendix
Appendix 10
Slide 11: Revenue By Product Family
Revenue By Product Family -Including GAAP to Non-GAAP constant currency reconciliation (in $M) Q1'22 Q2'22 Q3'22 Q4'22 FY'22 Q1'23* Cellular & Molecular 14.2 15.3 14.2 14.1 57.8 14.2 Product Lines - constant currency* Currency ADJ (0.3) Cellular & Molecular 14.2 15.3 14.2 14.1 57.8 13.9 Product Line
Slide 12: GAAP to Non-GAAP Reconciliation: Three Months Ended March 2023
GAAP to Non-GAAP Reconciliation: Three Months Ended March 2023 12